Skip to main content
SpringerLink
Log in

Efficacy of Acid Suppression Therapy

  • Chapter
  • First Online:
Functional Dyspepsia

  • 445 Accesses

Abstract

There is no clear evidence yet on the best treatment for functional dyspepsia. A variety of drugs are used to try and relieve dyspepsia. Antisecretory drugs are one of the mainstays of treatment. In a Cochrane meta-analysis of randomized trials, antisecretory drugs (H2 receptor antagonists and proton pump inhibitors) were found to be more effective than placebos, and there were no differences between H2 receptor antagonists and proton pump inhibitors. The effectiveness is independent of the subtype, dose, duration of treatment, and Helicobacter pylori status in both drugs. The effect of Helicobacter pylori eradication therapy, on the symptoms of functional dyspepsia, is modest. The effect of H2 receptor antagonists and proton pump inhibitors therapy on functional dyspepsia may be overestimated because most existing trials were performed utilizing the Rome I and II classification of functional dyspepsia.

More studies will be needed using the Rome IV criteria in the future, though meta-analyses suggest that acid suppressants are effective for the treatment of patients with functional dyspepsia. All trials to date followed up patients for less than 12 weeks. Trials evaluating therapies with a much longer follow-up will be required.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Stanghellini V, Chan FK, Hasler WL, Malagelada JR, Suzuki H, Tack J, et al. Gastroduodenal disorders. Gastroenterology. 2016;150:1380–92. https://doi.org/10.1053/j.gastro.2016.02.011.

    Article  PubMed  Google Scholar 

  2. Gerson LB, Triadafilopoulos G. A prospective study of oesophageal 24-h ambulatory pH monitoring in patients with functional dyspepsia. Dig Liver Dis. 2005;37(2):87–91. https://doi.org/10.1016/j.did.2004.09.021.

    Article  PubMed  CAS  Google Scholar 

  3. Bolling-Sternevald E, Lauritsen K, Aalykke C, Havelund T, Knudsen T, Unge P, et al. Effect of profound acid suppression in functional dyspepsia: a double-blind, randomized, placebo-controlled trial. Scand J Gastroenterol. 2002;37(12):1395–402. https://doi.org/10.1080/003655202762671260.

    Article  PubMed  CAS  Google Scholar 

  4. Sarnelli G, Vandenberghe J, Tack J. Visceral hypersensitivity in functional disorders of the upper gastrointestinal tract. Dig Liver Dis. 2004;36:371–6. https://doi.org/10.1016/j.did.2004.01.018.

    Article  PubMed  CAS  Google Scholar 

  5. Miwa H, nakajima K, Yamaguchi K, Fujimoto K, Veldhuyzen Van Zanten S, Kinoshita Y, et al. Generation of dyspeptic symptoms by direct acid infusion into the stomach of healthy Japanese subjects. Aliment Pharmacol Ther. 2007;26:257–64. https://doi.org/10.1111/j.1365-2036.2007.03367.x.

    Article  PubMed  CAS  Google Scholar 

  6. Talley NJ, Ford AC. Functional dyspepsia. N Engl J Med. 2015;373:1853–63. https://doi.org/10.1056/NEJMra1501505.

    Article  PubMed  CAS  Google Scholar 

  7. Walker MM, Aggarwal KR, Shim LS, Bassan M, Kalantar JS, Weltman MD, et al. Duodenal eosinophilia and early satiety in functional dyspepsia: confirmation of a positive association in an Australian cohort. J Gastroenterol Hepatol. 2014;29:474–9. https://doi.org/10.1111/jgh.12419.

    Article  PubMed  Google Scholar 

  8. Blum AL, Arnold R, Stolte M, Fischer M, Koelz HR. Short course acid suppressive treatment for patients with functional dyspepsia: results depend on Helicobacter pylori status. The Frosch Study Group. Gut. 2000;47(4):473–80. https://doi.org/10.1136/gut.47.4.473.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  9. Delattre M, Malesky M, Prinzie A. Symptomatic treatment of non-ulcer dyspepsia with cimetidine. Current Ther Res. 1985;37(5):980–91.

    Google Scholar 

  10. Gotthard R, Bodemar G, Brodin U, Jonsson KA. Treatment with cimetidine, antacid, or placebo in patients with dyspepsia of unknown origin. Scand J Gastroenterol. 1988;23(1):7–18. https://doi.org/10.3109/00365528809093840.

    Article  PubMed  CAS  Google Scholar 

  11. Hadi S. Clinical investigation of ranitidine in patients with gastritis. Clin Ther. 1989;11(5):590–4.

    PubMed  CAS  Google Scholar 

  12. Hansen JM, Bytzer P, Schaffalitzky D. Placebo-controlled trial of cisapride and nizatidine in unselected patients with functional dyspepsia. Am J Gastroenterol. 1998;93(3):368–74. https://doi.org/10.1111/j.1572-0241.1998.00368.x.

    Article  PubMed  CAS  Google Scholar 

  13. Kato M, Watanabe M, Konishi S, Kudo M, Konno J, Meguro T, et al. Randomized, double-blind, placebo controlled crossover trial of famotidine in patients with functional dyspepsia. Aliment Pharmacol Ther. 2005;21(Suppl. 2):27–31.

    Article  CAS  PubMed  Google Scholar 

  14. Kelbaek H, Linde J, Eriksen J, Mungaard S, Moesgaard F, Bonnevie O. Controlled clinical trial of treatment with cimetidine for non-ulcer dyspepsia. Acta Med Scand. 1985;217(3):281–7. https://doi.org/10.1111/j.0954-6820.1985.tb02696.x.

    Article  PubMed  CAS  Google Scholar 

  15. Muller P, Hotz J, Franz E, Simon B. Ranitidine in the treatment of non-ulcer dyspepsia. a placebo-controlled study in the Federal Republic of Germany. Arzneimittelforschung. 1994;44(10):1130–2.

    PubMed  CAS  Google Scholar 

  16. Nesland AA, Berstad A. Effect of cimetidine in patients with non-ulcer dyspepsia and erosive prepyloric changes. Scand J Gastroenterol. 1985;20(5):629–35. https://doi.org/10.3109/00365528509089708.

    Article  PubMed  CAS  Google Scholar 

  17. Olubuyide IO, Ayoola EA, Okubanjo AO, Atoba MA. Non-ulcer dyspepsia in Nigerians clinical and therapeutic results. Scand J Gastroenterol. 1986;124(21):83–7. https://doi.org/10.3109/00365528609093787.

    Article  CAS  Google Scholar 

  18. Saunders JH, Oliver RJ, Higson DL. Dyspepsia: incidence of a non-ulcer disease in a controlled trial of ranitidine in general practice. Br Med J (Clin Res Ed). 1986;292(6521):665–8. https://doi.org/10.1136/bmj.292.6521.665.

    Article  CAS  Google Scholar 

  19. Singal AK, Kumar A, Broor SL. Cimetidine in the treatment of non-ulcer dyspepsia: results of a randomized double-blind, placebo-controlled study. Curr Med Res Opin. 1989;11(6):390–7. https://doi.org/10.1185/03007998909110140.

    Article  PubMed  CAS  Google Scholar 

  20. Farup PG, Hovde O, Torp R, Wetterhus S. Patients with functional dyspepsia responding to omeprazole have a characteristic gastro-oesophageal reflux pattern. Scand J Gastroenterol. 1999;34(6):575–9. https://doi.org/10.1080/003655299750026029.

    Article  PubMed  CAS  Google Scholar 

  21. Fletcher J, Derakhshan MH, Jones GR, Wirz AA, McColl KE. BMI is superior to symptoms in predicting response to proton pump inhibitor: randomised trial in patients with upper gastrointestinal symptoms and normal endoscopy. Gut. 2011;60(4):442–8. https://doi.org/10.1136/gut.2010.228064.

    Article  PubMed  Google Scholar 

  22. Hengels KJ. Therapeutic efficacy of 15mg lansoprazole mane in 269 patients suffering from non-ulcer dyspepsia (NUD): a multicentre, randomised, double-blind study. Gut. 1998;43(Suppl 2):A89.

    Google Scholar 

  23. Iwakiri R, Tominaga K, Furuta K, Inamori M, Furuta T, Masuyama H, et al. Randomised clinical trial: rabeprazole improves symptoms in patients with functional dyspepsia in Japan. Aliment Pharmacol Ther. 2013;38:729–40. https://doi.org/10.1111/apt.12444.

    Article  PubMed  CAS  Google Scholar 

  24. Peura DA, Kovacs TO, Metz DC, Siepman N, Pilmer BL, Talley NJ. Lansoprazole in the treatment of functional dyspepsia: two double-blind, randomized, placebo controlled trials. Am J Med. 2004;116(11):740–8. https://doi.org/10.1016/j.amjmed.2004.01.008.

    Article  PubMed  CAS  Google Scholar 

  25. Suzuki H, Kusunoki H, Kamiya T, Futagami S, Yamaguchi Y, Nishizawa T, et al. Effect of lansoprazole on the epigastric symptoms of functional dyspepsia (ELFstudy): a multicentre, prospective, randomized, double-blind, placebo-controlled clinical trial. United European Gastroenterol J. 2013;1(6):445–52. https://doi.org/10.1177/2050640613510904.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  26. Talley NJ, Meineche-Schmidt V, Pare P, Duckworth M, Raisanen P, Pap A, et al. Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the BOND and OPERA studies). Aliment Pharmacol Ther. 1998;12(11):1055–65.

    Article  CAS  PubMed  Google Scholar 

  27. Talley NJ, Vakil N, Lauritsen K, Van Zanten VS, Flook N, Bolling-Sternevald E, et al. Randomized-controlled trial of esomeprazole in functional dyspepsia patients with epigastric pain or burning: does a 1-week trial of acid suppression predict symptom response? Aliment Pharmacol Ther. 2007;26(5):673–82. https://doi.org/10.1111/j.1365-2036.2007.03410.x.

    Article  PubMed  CAS  Google Scholar 

  28. Tominaga K, Suzuki H, Umegaki E, Kusunoki H, Tomotsugu N, Higuchi K, et al. Rabeprazole improves the symptoms of functional dyspepsia–a double blind randomized placebo-controlled multi-center trial in Japan: the CAESAR Study. Gastroenterology. 2010;138(5 Suppl 1):S55.

    Google Scholar 

  29. Van Rensburg C, Berghofer P, Enns R, Dattani ID, Maritz JF, Gonzalez Carro P, et al. Efficacy and safety of pantoprazole 20 mg once daily treatment in patients with ulcer-like functional dyspepsia. Curr Med Res Opin. 2008;24(7):2009–18. https://doi.org/10.1185/03007990802184545.

    Article  PubMed  CAS  Google Scholar 

  30. Van Zanten SV, Armstrong D, Chiba N, Flook N, White RJ, Chakraborty B, et al. Esomeprazole 40 mg once a day in patients with functional dyspepsia: the randomized, placebo-controlled “ENTER” trial. Am J Gastroenterol. 2006;101(9):2096–106. https://doi.org/10.1111/j.1572-0241.2006.00751.x.

    Article  PubMed  CAS  Google Scholar 

  31. Wong WM, Wong BCY, Hung WK, Yee YK, Yip AWC, Szeto ML, et al. Double blind, randomized, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients. Gut. 2002;51(4):502–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Moayyedi P, Soo S, Deeks J, Delaney B, Innes M, Forman D. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2006;4:CD001960. https://doi.org/10.1002/14651858.CD001960.pub3.

    Article  Google Scholar 

  33. Pinto-Sanchez MI, Yuan Y, Bercik P, Moayyedi P. Proton pump inhibitors for functional dyspepsia. Cochrane Database Syst Rev. 2017;3:CD011194. https://doi.org/10.1002/14651858.CD011194.pub2.

    Article  PubMed  Google Scholar 

  34. Abramowitz J, Thakkar P, Isa A, Truong A, Park C, Rosenfeld RM. Adverse event reporting for proton pump inhibitor therapy: An overview of systematic reviews. Otolaryngol Head Neck Surg. 2016;155(4):547–54. https://doi.org/10.1177/0194599816648298.

    Article  PubMed  Google Scholar 

  35. Talley NJ, Vakil NB, Moayyedi P. American Gastroenterological Association technical review on the evaluation of dyspepsia. Gastroenterology. 2005;129:1756–80. https://doi.org/10.1053/j.gastro.2005.09.20.

    Article  PubMed  Google Scholar 

  36. Klotz U, Schwab M, Treiber G. CYP2C19 polymorphism and proton pump inhibitors. Basic Clin Pharmacol Toxicol. 2004;95(1):2–8. https://doi.org/10.1111/j.1600-0773.2004.pto950102.x.

    Article  PubMed  CAS  Google Scholar 

  37. Furuta T, Sugimoto M, Shirai N, Ishizaki T. CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor. Pharmacogenomics. 2007;8(9):1199–210. https://doi.org/10.2217/14622416.8.9.1199.

    Article  PubMed  CAS  Google Scholar 

  38. Dillon JF, Finch PJ, Baxter G. A comparison of lansoprazole vs ranitidine in the treatment of functional ulcer-like dyspepsia as defined by the Rome II criteria. Gut. 2004;53(Suppl VI):A285.

    Google Scholar 

  39. Moayyedi P, Soo S, Deeks J, Forman D, Harris A, Innes M, et al. Systematic review: antacids, H2-receptor antagonists, prokinetics, bithmuth and sucralfate therapy for non-ulcer dyspepsia. Aliment Pharmacol Ther. 2003;17:1215–27. https://doi.org/10.1046/j.0269-2813.2003.01575.x.

    Article  PubMed  CAS  Google Scholar 

  40. Gudjonsson H, Oddsson E, Bjomsson S, Gunnlaugsson O, Theodors A, Jonasson TA, et al. Efficacy of sucralfate in treatment of non-ulcer dyspepsia. A double-blind placebo-controlled study. Scand J Gastroenterol. 1993;28(11):969–72. https://doi.org/10.3109/00365529309098293.

    Article  PubMed  CAS  Google Scholar 

  41. Kairaluma MI, Hentilae R, Alavaikko M, Kellosalo J, Stahlberg M, Jalovaara P, et al. Sucralfate versus placebo in treatment of non-ulcer dyspepsia. Am J Med. 1987;83(3B):51–5. https://doi.org/10.1016/0002-9343(87)90828-X.

    Article  Google Scholar 

  42. Kumar M, Yachha SK, Aggarwal R, Shukla S, Pandey R, Prasad KN, et al. Healing of chronic antral gastritis: effect of sucralfate and colloidal bismuth subcitrate. Indian J Gastroenterol. 1996;15(3):90–3.

    PubMed  CAS  Google Scholar 

  43. Moayyedi P, Shelly S, Deeks JJ, et al. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. BMJ. 2000;321(7262):659–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hattori Clinic, Kumamoto, Kumamoto City, Kumamoto, Japan

    Kouichi Sakurai & Hiroko Suda

Authors
  1. Kouichi Sakurai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiroko Suda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kouichi Sakurai .

Editor information

Editors and Affiliations

  1. Premier Developmental Research of Medicine, Osaka Medical College, Takatsuki, Osaka, Japan

    Kazunari Tominaga

  2. Department of General Medicine, Kawasaki Medical School, Kurashiki, Okayama, Japan

    Hiroaki Kusunoki

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Sakurai, K., Suda, H. (2018). Efficacy of Acid Suppression Therapy. In: Tominaga, K., Kusunoki, H. (eds) Functional Dyspepsia. Springer, Singapore. https://doi.org/10.1007/978-981-13-1074-4_11

Download citation

  • DOI: https://doi.org/10.1007/978-981-13-1074-4_11

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-13-1073-7

  • Online ISBN: 978-981-13-1074-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation